Multiple myeloma: burden of disease analysis in some countries of latin america

In Latin America, there is no systematic information to determine and monitor multiple myeloma. The objective of this study was estimate the annual burden of multiple myeloma disease in five Latin American healthcare systems through the number of attended patients, hospitalizations and specific deaths, by age group. Using specific ICD-10:C90 coded registries from National Healthcare Systems' databases of Argentina, Colombia, Peru, Ecuador and Venezuela, we retrieved/analyzed 2015 complete year data for: attended and hospitalized patients stratified by age groups, and for specific deaths. In 2015, the total number of cases attended (prevalence of cases attended) was: Argentina 1.278 (2.96), Colombia 875 (1.82), Ecuador 311 (1.91), Peru 603 (1.94) and Venezuela 758 (2.48); ≥50 years, represented on average for the five countries 86.88% (81.94%-91.83%) of total. Hospitalized cases were (average hospitalization rate): Argentina 1.002 (1.31), Colombia 639 (1.51), Ecuador 218 (1.48), Peru 452 (1.52) and Venezuela 559 (1.34); on average ≥50 years, represented 86.21% (80.12%-92.29%) of total. Hospitalization for ≥60 years vs. 50-59 years (62.86% [53.20%-72.52%] vs. 23.35% [18.67%-28.03%]) increased ~2.7 times, and this population (≥ 60 years) is expected to increase ~41% by 2025. Average mortality rate was 1.28 [0.82-2.62]. Multiple myeloma represents a burden on the health of elderly population and healthcare systems, and is expected to grow as the population ages (AU)

En Latinoamérica no existe información sistematizada para determinar/monitorizar el mieloma múltiple. El objetivo del estudio fue estimar la carga anual de enfermedad del mieloma múltiple en cinco sistemas de salud latinoamericanos mediante el número de pacientes atendidos, hospitalizaciones y muertes específicas, por grupo de edad. Utilizando registros específicos codificados por CIE-10: C90 de bases de datos de los Sistemas Nacionales de Salud de Argentina, Colombia, Perú, Ecuador y Venezuela, obtuvimos y analizamos datos de 2015 (año completo) para pacientes atendidos y hospitalizados estratificados por grupo etario y para muertes específicas. En 2015, el número total de casos atendidos (prevalencia de casos atendidos) fue: Argentina 1.278 (2.96), Colombia 875 (1.82), Ecuador 311 (1.91), Perú 603 (1.94) y Venezuela 758 (2.48); ≥50 años, representaron en promedio para los cinco países 86.88% (81.94% - 91.83%) del total. Los casos hospitalizados fueron (tasa promedio de hospitalización): Argentina 1.002 (1.31), Colombia 639 (1.51), Ecuador 218 (1.48), Perú 452 (1.52) y Venezuela 559 (1.34); en promedio ≥50 años, representaron 86.21% (80.12%-92.29%) del total. La hospitalización de ≥ 60 años vs. 50-59 años (62.86% [53.20% - 72.52%] vs. 23.35% [18.67%-28.03%]) aumentó ~2.7 veces, y esta población (≥ 60 años) se espera aumente ~41% para 2025. La tasa de mortalidad promedio fue 1.28 [0.82-2.62]. El mieloma múltiple representa una carga para la salud de los adultos mayores y los sistemas de salud, y se espera aumente conforme envejece la población (AU)

Psoríase em pacientes HIV positivo / Psoriasis in a seropositive HIV patient

Two patients with the acquired immunodeficiency syndrome (AIDS) developed psoriasis, one of them presenting the more severe form and the other one the milder form of the disease, were treated with zidovudine per oral via, 200mg 3 times a day. In the first case the therapeutical response was complete. No lesion was verified in the patient after 9 months under maintenance schedule. In the second case, despite the response being clear, after 6 months of treatment, the patient still presented furfuraceous scalings at limbs ever under the medication schedule.